| Literature DB >> 25897811 |
Tero Ahola1, Therese Couderc, Therese Courderc, Lisa F P Ng, David Hallengärd, Ann Powers, Marc Lecuit, Mariano Esteban, Andres Merits, Pierre Roques, Peter Liljeström.
Abstract
Currently, there are no licensed vaccines or therapies available against chikungunya virus (CHIKV), and these were subjects discussed during a CHIKV meeting recently organized in Langkawi, Malaysia. In this review, we chart the approaches taken in both areas. Because of a sharp increase in new data in these fields, the present paper is complementary to previous reviews by Weaver et al. in 2012 and Kaur and Chu in 2013 . The most promising antivirals so far discovered are reviewed, with a special focus on the virus-encoded replication proteins as potential targets. Within the vaccines in development, our review emphasizes the various strategies in parallel development that are unique in the vaccine field against a single disease.Entities:
Keywords: Antibodies; Antiviral; Attenuated virus; Chikungunya; DNA chimeric viruses; Polymerase; Protease; Vaccine; Virus-like particles
Mesh：
Substances：
Year: 2015 PMID： 25897811 DOI： 10.1089/vbz.2014.1681
Source DB: PubMed Journal: Vector Borne Zoonotic Dis ISSN： 1530-3667 Impact factor: 2.133